From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy - PubMed
6 hours ago
- #precision immunotherapy
- #cellular therapy
- #B-cell malignancies
- CAR-T therapy uses lineage-associated antigens like CD19, leading to on-target off-tumor toxicity such as B-cell aplasia and immune dysfunction.
- CAAR-T therapy targets disease-specific immunoglobulin idiotypes, potentially sparing normal B cells, with applications explored in autoimmune diseases.
- CAAR-T is a precision platform for B-cell malignancies requiring validation, not a near-term replacement for CAR-T, with various barriers to address.